Zobrazeno 1 - 9
of 9
pro vyhledávání: '"J J, Koldenhof"'
Autor:
Petronella O. Witteveen, C.M.L. van Herpen, C. del Grande, A.N.M. Wymenga, B. van Doorn, J. J. Koldenhof, Hans Gelderblom, Chantal M. L. Driessen, Ann Hoeben, Christine B. Boers-Doets, J. W. B. de Groot, R. T. Lugtenberg
Publikováno v:
Supportive Care in Cancer
Supportive Care in Cancer, 29, 7, pp. 3497-3506
Supportive Care in Cancer, 29(7), 3497-3506. Springer, Cham
Supportive Care in Cancer, 29, 3497-3506. SPRINGER
Supportive Care in Cancer, 29, 3497-3506
Supportive Care in Cancer, 29, 7, pp. 3497-3506
Supportive Care in Cancer, 29(7), 3497-3506. Springer, Cham
Supportive Care in Cancer, 29, 3497-3506. SPRINGER
Supportive Care in Cancer, 29, 3497-3506
Purpose Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used. The main purpose of the present study is to gain information about the different skincare
Autor:
Sigrid C Vervoort, Karijn P M Suijkerbuijk, Everlien de Graaf, S. C. C. M. Teunissen, Michael Echteld, J. J. Koldenhof, Ellen J M de Nijs, Jan B Vos, Danielle Zweers, Frederieke H van der Baan, Petronella O. Witteveen, Ginette M Hesselmann, Alexander de Graeff
Publikováno v:
Cancer Medicine, 2020 (9), 6111-6121
Cancer Medicine, Vol 9, Iss 17, Pp 6111-6121 (2020)
Cancer Medicine
Cancer Medicine, Vol 9, Iss 17, Pp 6111-6121 (2020)
Cancer Medicine
Background The Utrecht Symptom Diary (USD) is a Dutch and adapted version of the Edmonton Symptom Assessment System, a patient‐reported outcome measurement (PROM) tool to asses and monitor symptoms in cancer patients. This study analyses the validi
Publikováno v:
European Journal of Cancer. 87:216-218
Autor:
J. J. Koldenhof, Karijn P M Suijkerbuijk, Cheryl P. Bruijnen, Erwin H J Tonk, Frederiek van den Bos, Petronella O. Witteveen, Mariëlle H. Emmelot Vonk, Rik Jasper Verheijden
Publikováno v:
Journal of Clinical Oncology. 38:e24028-e24028
e24028 Background: Immune checkpoint inhibitors (ICIs) have changed the melanoma treatment landscape by inducing durable responses and significantly improving survival. ICI can cause immune-related adverse events (irAES) ranging from mild to life thr
Publikováno v:
European Journal of Cancer Care, 27(2). Wiley-Blackwell
Adverse events (AEs) of epidermal growth factor inhibitors (EGFRi) influence well-being with a risk to dose modifications (DMs). Hereby, clinical benefit of treatment might be affected. This retrospective cohort study was set up to gain insight into
Autor:
A.C.M. van Lindert, Karijn P M Suijkerbuijk, Erwin H J Tonk, Saskia C.C.M. Teunissen, Petronella O. Witteveen, E.G. Verberne, F.H. van der Baan, Rik J Verheijden, J. van der Stap, J. J. Koldenhof
Publikováno v:
Annals of Oncology. 30:v837
Background PD(L)1-inhibitors can cause immune-related adverse events (irAEs.). IrAEs may be under-recognized and their influence on health-related quality of life (HRQL) underestimated. At this point, insight into patient-reported symptom prevalence
Publikováno v:
Annals of Oncology. 29:viii684
Autor:
M L R, Tjin-A-ton, C, van Montfrans, J J, Koldenhof, V, Sigurdsson, E E, Voest, P O, Witteveen
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 151(17)
Inhibition of the epidermal growth-factor receptor (EGFR) is a new strategy in the treatment of solid malignancies. Two men, aged 65 and 59 years, with a metastasized renal carcinoma and a 51-year-old man with a metastasized melanoma developed an acn
Publikováno v:
European Journal of Cancer. 51:S261